Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 171

    1.

    Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand.

    Niparuck P, Sorakhunpipitkul L, Atichartakarn V, Chuncharunee S, Ungkanont A, Aungchaisuksiri P, Puavilai T, Jootar S.

    J Hematol Oncol. 2010 Jan 5;3:1.

    PMID:
    20051128
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.

    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.

    Cancer. 2010 Jul 1;116(13):3143-51.

    PMID:
    20564642
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.

    Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T, Pregno P, Bertola A, Cavallo F, Ciccone G, Boccadoro M.

    Eur J Haematol. 2005 Nov;75(5):391-5.

    PMID:
    16191088
    [PubMed - indexed for MEDLINE]
    4.

    Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

    Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.

    Haematologica. 2005 Dec;90(12):1650-4.

    PMID:
    16330438
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    Thalidomide and dexamethasone combination for refractory multiple myeloma.

    Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N.

    Ann Oncol. 2001 Jul;12(7):991-5.

    PMID:
    11521808
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.

    Offidani M, Corvatta L, Polloni C, Gentili S, Mele A, Rizzi R, Catarini M, Caraffa P, Samori A, Blasi N, Ferranti M, Malerba L, Brunori M, Leoni P.

    Ann Hematol. 2011 Dec;90(12):1449-56. Epub 2011 Mar 25.

    PMID:
    21437586
    [PubMed - indexed for MEDLINE]
    7.

    Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.

    Palumbo A, Larocca A, Falco P, Sanpaolo G, Falcone AP, Federico V, Canepa L, Crugnola M, Genuardi M, Magarotto V, Petrucci MT, Boccadoro M.

    Leukemia. 2010 May;24(5):1037-42. Epub 2010 Apr 8.

    PMID:
    20376079
    [PubMed - indexed for MEDLINE]
    8.

    Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

    Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N.

    J Clin Oncol. 2009 Apr 10;27(11):1788-93. Epub 2009 Mar 9.

    PMID:
    19273705
    [PubMed - indexed for MEDLINE]
    9.

    [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].

    Yuan ZG, Hou J, Wang DX, Fu WJ, Chen YB, Xi H.

    Zhonghua Nei Ke Za Zhi. 2008 Feb;47(2):102-6. Chinese.

    PMID:
    18683793
    [PubMed - indexed for MEDLINE]
    10.

    Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.

    Kyriakou C, Thomson K, D'Sa S, Flory A, Hanslip J, Goldstone AH, Yong KL.

    Br J Haematol. 2005 Jun;129(6):763-70.

    PMID:
    15953002
    [PubMed - indexed for MEDLINE]
    11.

    Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.

    Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.

    Ann Hematol. 2010 Sep;89(9):905-12. Epub 2010 Mar 27.

    PMID:
    20349060
    [PubMed - indexed for MEDLINE]
    12.

    Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.

    Zemanova M, Scudla V, Adam Z, Gregora E, Pour L, Minarik J, Pavlicek P, Pika T, Bacovsky J.

    Neoplasma. 2008;55(4):345-9.

    PMID:
    18505347
    [PubMed - indexed for MEDLINE]
    13.

    Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).

    Eom HS, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, Jin JY, Do YR, Oh SJ, Suh C, Seong CM, Kim CS, Lee DS, Lee JH.

    Ann Hematol. 2010 May;89(5):489-97. Epub 2009 Dec 10.

    PMID:
    20012045
    [PubMed - indexed for MEDLINE]
    14.

    Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.

    Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.

    Eur J Haematol. 2007 Apr;78(4):297-302. Epub 2007 Feb 5.

    PMID:
    17286608
    [PubMed - indexed for MEDLINE]
    15.

    Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.

    Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG.

    Br J Haematol. 2010 Feb;148(4):562-8. Epub 2009 Nov 16.

    PMID:
    19919652
    [PubMed - indexed for MEDLINE]
    16.

    Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

    Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R, McKendrick J, Briggs P, Seymour JF, Lillie K, Smith JG, Zeldis JB, Prince HM.

    Blood. 2003 Jul 1;102(1):69-77. Epub 2003 Mar 13.

    PMID:
    12637329
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.

    Barlogie B.

    Semin Hematol. 2003 Oct;40(4 Suppl 4):33-8. Review.

    PMID:
    15015894
    [PubMed - indexed for MEDLINE]
    18.

    Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

    Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.

    Eur J Haematol. 2006 Apr;76(4):273-7.

    PMID:
    16519697
    [PubMed - indexed for MEDLINE]
    19.

    Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

    Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

    Blood. 2008 Dec 1;112(12):4445-51. Epub 2008 Sep 17.

    PMID:
    18799726
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Transplantation as salvage therapy for high-risk patients with myeloma in relapse.

    Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G.

    Bone Marrow Transplant. 2002 Dec;30(12):873-8.

    PMID:
    12476279
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk